BioGenCell is led by a team of seasoned executives who have many years of executive and technical experience in the biotechnology industry. The founding team has a proven track record in the creation and manufacturing of commercially available cellular products, which were proven safe and beneficial for treating severe heart diseases and peripheral arterial diseases.
Dr. Yael Porat, PHD
Prof. Michael Belkin, MD
Chief Scientific Officer, Co-Founder
Mr. Eyal Peleg, CPA, MBA
Co-Founder, CHIEF FINANCIAL officer
BioGenCell EU Administrator
Marc Dechamps is a biologist with extensive experience of more than 30 years in the Pharmaceutical industry, with expertise in market development for new products including infectious diseases, immunological disorders, cancer, CNS diseases and vaccines.
Michael Barnea, Adv
Dr. Peter Stangier
Strategic Planning and BD
Dr. Stangier is partner at ACCELERO Gmbh, founder and Managing Director of ‘From Data To Decisions’ since 2013. Dr. Stangier is knowledgeable strategic planner with over 20 years of experience who has worked for Big Pharma in mass markets to medium size and start up biotech companies.